Minapharm Pharmaceuticals (CAI:MIPH) Total Liabilities: E£6,790 Mil (As of Dec. 2025)


CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£698.08
GF Value E£362.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Total Liabilities?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 Total Liabilities is E£6,790 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was E£6,790 Mil.

Minapharm Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2025 (E£7,872.92 Mil) to Sep. 2025 (E£7,443.47 Mil) and declined from Sep. 2025 (E£7,443.47 Mil) to Dec. 2025 (E£6,789.86 Mil).

Minapharm Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (E£5,186.25 Mil) to Dec. 2024 (E£7,594.26 Mil) but then declined from Dec. 2024 (E£7,594.26 Mil) to Dec. 2025 (E£6,789.86 Mil).

Minapharm Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Total Liabilities Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
2,162.61 3,765.30 5,186.25 7,594.26 6,789.86

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,594.26 7,738.52 7,872.92 7,443.47 6,789.86
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Minapharm Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4807.024+(1762.999+219.832
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6,790

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=13148.14-6358.285
=6,790

Minapharm Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4807.024+(1762.999+219.832
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6,790

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=13148.14-6358.285
=6,790

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of E£6,790 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Total Liabilities of E£6,790 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Total Liabilities too high?
Minapharm Pharmaceuticals' current Total Liabilities is E£6,790 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Total Liabilities compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Total Liabilities of E£6,790 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Total Liabilities is E£6,790 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current Total Liabilities is E£6,790 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Total Liabilities is E£6,790 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Total Liabilities: E£6,790 Mil
  • GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08
Price
E£362.31
GF Value